Today: 13 June 2026
Browse Category

LSE:CMCX 2 February 2026

Stock Market Today

  • Cintas (CTAS) Stock Valuation Mixed Amid UniFirst Deal Expectations
    June 13, 2026, 3:33 PM EDT. Cintas Corp (CTAS) stock closed at $176.28, reflecting mixed returns with a 2% decline over the past week and a 4.7% drop year to date, despite gains over three and five years. Investors are reassessing value amid maturity in the service sector and deal expectations with UniFirst. A Discounted Cash Flow (DCF) analysis estimates Cintas' intrinsic value at $187.68 per share, indicating the stock trades at a 6.1% discount and suggesting it is fairly valued. The company scored 2 out of 6 on value checks, highlighting some undervaluation but signaling caution. Market watchers are urged to monitor shifts in assumptions that could affect valuations and consider the broader strategic narrative beyond the numbers.

Latest articles

KLA Jumps After 10-for-1 Stock Split; AI Chip Boom Lifts Hopes on Tools

KLA Jumps After 10-for-1 Stock Split; AI Chip Boom Lifts Hopes on Tools

13 June 2026
KLA soared 5.55% to $254.54 on its first split-adjusted day after a 10-for-1 stock split and analyst price target hikes tied to AI-driven chip equipment demand, but with the stock now above several split-adjusted targets, investors face heightened risk ahead of the fiscal Q4 report, which will be the next key catalyst for revenue, earnings, and AI-linked demand guidance.
Pfizer trades around $26 with dividend in focus, drug-price worries linger

Pfizer trades around $26 with dividend in focus, drug-price worries linger

13 June 2026
Pfizer closed at $26.21, up 0.15%, outperforming the Health Care Select Sector SPDR ETF despite new German drug-pricing pressures and a European legal setback; investors are focused on the 6.56% dividend yield, reaffirmed 2026 guidance, and pipeline progress in obesity and oncology as Q2 earnings on August 4 approach.
Go toTop